We support boolean queries, use +,-,<,>,~,* to alter the weighting of terms
Neuroflocks is an unique tool to navigate tweets from the past SfN meeting and find out the hot topics tweeted during the conference (SfN-2010). We have collected all tweets using the hashtag #sfn10 and made them browsable via a simple visual search interface. Type in the word you want to search for and only tweets containing that word will light up! You can click on single tweets, browse the tweet content, click on the Twitter user and find new Neuroscience-enthusiast twitterers! You can also find out what was really HOT during the conference (Re-Tweeted tweets, RT have been color coded). Moreover, the tweets follow a time gradient from the inside out: the spiral's center contains tweets from the beginning of the meeting while tweets on the outside of the spiral were tweeted at the end of the meeting. Enhanced versions of neuroflocks are currently under development !!!
Portal for sleep-disordered breathing (SDB) in an elderly cohort of Japanese-American men under surveillance for Alzheimer disease (AD) and other dementias. Data to assess relationships between SDB and cognitive performance in late life.
Core facility that provides consultation on the use of viral vector technologies as well as custom design and production services for multiple vector types. The GT3 facilitates the use of these research tools by Salk researchers and others across diverse fields of study such as systems neuroscience, stem cell biology, metabolism, ageing, cancer biology and gene therapy. The GT3 core is a designated Cancer Center Council (C3) core facility. Cancer Center members from participating C3 institutes have preferential rates.
Collection of structures and annotations of biologically relevant lipids that contains unique lipid structures. Structures of lipids from : LIPID MAPS Consortium's core laboratories and partners; lipids identified by LIPID MAPS experiments; biologically relevant lipids manually curated from LIPID BANK, LIPIDAT, Lipid Library, Cyberlipids, ChEBI and other public sources; novel lipids submitted to peer-reviewed journals; and computationally generated structures for appropriate classes. All the lipid structures adhere to the structure drawing rules proposed by the LIPID MAPS consortium. A number of structure viewing options are offered: gif image (default), Chemdraw (requires Chemdraw ActiveX/Plugin), MarvinView (Java applet) and JMol (Java applet). All lipids have been classified using the LIPID MAPS Lipid Classification System. Each lipid structure has been assigned a LIPID MAPS ID (LM_ID) which reflects its position in the classification hierarchy. In addition to a classification-based retrieval of lipids, users can search using either text-based or structure-based search options.
Software tool to identify pockets on protein surface to predict ligand-binding sites.
Offers manufacturing of cellular and biologics for safety and initial efficacy testing in first–in– human, pilot, and Phase I clinical trials. Facilitates bench–to–bed translation into novel cellular therapies. Provides focused scientific, technical, and regulatory support for investigator-initiated investigational new drug applications (INDs) in cell and gene therapy. Current and completed trials include hematologic malignancies multiple myeloma, breast cancer, prostate cancer, glioblastoma, neuroblastoma, and pancreatic cancer. The potential applications of cellular therapy and biologics are not limited to cancer, a large number of disease indications such as cardiovascular, autoimmune diseases, diabetes, neurological diseases, etc.
Consortium that brings together the kidney community (patient advocacy groups, industry, government agencies, and professional organizations) to overcome existing challenges, including regulatory and nonregulatory barriers, and optimize the development and safety of products that impact kidney health including drugs, devices, biologics, and food products. The goals of the consortium are to: * Facilitate dialogue and research that informs regulatory processes with regard to the kidney health of patients being treated for kidney-related as well as other diseases. * Assess current medical therapies and diagnostics to identify areas in need of greater innovation and/or better defined regulatory pathways. * Develop innovative and efficient trial designs appropriate to answer the most important questions related to kidney health. * Establish expert consensus around common terminology and key definitions related to kidney health. * Develop approaches to the systematic collection of retrospective or prospective data, such as registries and/or global databases, and establishment of data standards. * Coordinate think tanks, public forums, educational exchanges, and other events to promote discussion and updates on topics in kidney health pertaining to drug, device, biologics, and food product development and evaluation. * Create transparent infrastructure and processes that facilitate collaboration and communication among the greater nephrology community and the FDA, including: * Seek input from all stakeholders (including nephrologists and other health professionals, patient groups, industry, the National Institutes of Health, the Centers for Medicare and Medicaid Services, the Health Resources and Services Administration, and other federal agencies). * Leverage previously conducted and ongoing clinical studies, research infrastructure, and databases. * Create an open and efficient mechanism for encouraging and objectively evaluating potential projects submitted to KHI. * Involve consortium members in the selection and execution of projects. * Establish systems to optimize post-market surveillance of products that affect kidney health, either intentionally or via adverse drug reactions. * Author journal articles and white papers regarding key issues, describing opportunities and challenges and proposing solutions, as well as promoting execution of these solutions.
SoftwareR package from CRAN for statistical modeling. Includes growth curve comparisons, limiting dilution analysis (aka ELDA), mixed linear models, heteroscedastic regression, inverse-Gaussian probability calculations, Gauss quadrature and a secure convergence algorithm for nonlinear models. Includes advanced generalized linear model functions that implement secure convergence, dispersion modeling and Tweedie power-law families.
Core within Indiana Center for Diabetes and Metabolic Diseases that offers services that facilitate conduct of research involving human subjects, including providing low-cost, high quality analyte measurements for variety of hormones, cytokines, lipids and other analytes. Its human studies services include metabolic phenotyping (e.g. GTT, clamp studies, tracer studies), and access to a biobank of human tissues and serum.
A public Solr index for the Gene Ontology. This index will replace some of the query functionality for GOOSE as well as become the new backend for AmiGO 2 and other services.
Software tool for variant calling with reference and de novo assembly of genomes. The heart of DISCOVAR is a de novo genome assembler which can generate de novo assemblies for both large and small genomes.
Provides numerous types of mass-spectrometry based proteomics services, including global proteome quantitation, affinity purification-mass spectrometry, targeted mass spectrometry analysis for precise quantitation, post-translational modification analysis, and a variety of consulting services.
Nonprofit organization committed exclusively to support research seeking the cause of the potentially debilitating kidney disease Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome, improve treatment and find a cure. NephCure Kidney International is: * Committed to funding research around the globe that will continue to move us closer to an improved treatment and a cure. * The primary source of information on Nephrotic Syndrome and FSGS. * Leading the charge for legislative action to provide more federal funding for research into Nephrotic Syndrome and FSGS. * Working to attract researchers to this field. * Educating the public and raising awareness about Nephrotic Syndrome and FSGS.
Diretta Juventus-Inter dalle 20.30: probabili formazioni e dove vederla in tv http://bit.ly/2ITALIA TORINO – «Inter? Più importante lo Young Boys». Massimiliano Allegri ha provato a stemperare così la tensione di una partita che mai sarà come le altre. Sarà il primo derby d’Italia senza Buffon in porta, il primo senza Marotta bianconero: «La Juve non ha ammazzato il campionato – ha detto il tecnico nella conferenza della vigilia -. Si vince solo a maggio, servono almeno trenta vittorie». Spalletti, che farà a meno di Nainggolan, ha invitato la squadra ad andare all’Allianz con coraggio e personalità: «Le nostre condizioni fisiche e mentali sono ottime, dipenderà da noi accorciare o meno questo distacco». Juventus già a 40, Inter a 29. La sfida di questa sera potrebbe dare un’ulteriore sterzata al campionato. Segui tutto in diretta dalle 20.30 su TORINO - L’ultima volta assieme è stata a Mosca, 15 luglio. La Croazia si ferma a un passo dal Paradiso, battuta nella finale mondiale dalla Francia. Finisce 4-2, Mario Mandzukic e Ivan Perisic vanno di nuovo in gol assieme, come era capitato nella rimonta vincente in semifinale contro l’Inghilterra (con assist di Perisic a Mandzukic per il 2-1 della vittoria). Non basta per regalare un sogno a una nazione di poco più di quattro milioni di abitanti, che si è stretta intorno alla squadra fin dal primo giorno dell’avventura russa, a cominciare dalla presidentessa Kolinda Grabar-Kitarovic, presente in tribuna allo stadio Luzniki. Quel 15 luglio è anche il giorno dell’addio di Mandukic alla Nazionale con la maglia a scacchi bianco e rossa. Il centravanti dice basta, dopo aver portato la Croazia fin dove mai era arrivata prima. Perisic invece continua, come continua Marcelo Brozovic, autore di un torneo finalmente all’altezza delle aspettative. Il terzetto si ritrova di fronte questa sera, nella classicissima del campionato italiano: Mandzukic con la Juventus, il duo Perisic-Brozovic con l’Inter. Se nessuno ne parla, vuol dire che non esiste. Si applichi questa meccanica perversa a Juventus-Inter, e otterremo un trentennio di polemiche arbitrali a senso unico. Sì, perché l'episodio di Iuliano e Ronaldo, riesumato anche in questa stagione con tanto di botta e risposta tra Simoni e Ceccarini, ha ormai assunto una valenza quasi mitica agli occhi degli anti-juventini. Un peso leggendario, che permette così di inserirlo fra gli scandali, fra i "furti" (quasi fosse chiamato in causa il codice penale), da raccontare alle generazioni future. Poco importa che la realtà sia diversa: basta parlarne. E lo stesso modello calza a meraviglia alla mancata espulsione Pjanic della scorsa stagione, così come - in generale e con una risonanza minore - a tutti gli episodi che coinvolgono errori veri o presunti pro-Juve. Peccato che poi, se solleviamo questa tenda di complottismo, nella storia degli Juve-Inter si possono notare decine di "furti" colorati di nerazzurro. Peccato che non facciano rumore come Iuliano e Ronaldo...
Core which assists investigators to quantify and phenotypically characterize cell populations that contribute to the metabolic, immunologic and developmental programs of diabetes and its complications; and to purify populations of cells of relevance to diabetes and its complications.
Consortium to discover and map the genes that contribute to Alzheimer's disease and completely understand the role inheritance plays. To achieve this goal, they will work to identify all the genes that contribute to the risk of developing this disease. Investigators will have access to combined genetic data from a large number of Alzheimer's disease subjects and compare it to genetic data from an equally large number of elderly people who do not have Alzheimer's. In the initial phase of the work, more than 20,000 people with Alzheimer's and about 20,000 healthy elderly subjects will be compared. As the study progresses, 10,000 additional people with Alzheimer's and the same number of healthy elderly subjects will be added to the study. The subjects for these studies come from different Alzheimer research project locations across Europe, the UK, the US, and Canada. Data is available from their 2014 publication in Translational Psychiatry at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944635/ (http://www.ncbi.nlm.nih.gov/pubmed/24495969) Currently, there is no public access to the raw individual level genetic data because of privacy considerations. Researchers working with US cohorts deposit data in the database of genotypes and phenotypes (dbGaP), where it is available to all researchers who can show that they are able to guarantee the security of the data. After scanning the DNA of over 74,000 patients and controls from 15 countries, the IGAP consortium reported 11 new regions of the genome involved in late-onset Alzheimer's disease. IGAP published its results in Nature Genetics on October 27, http://www.ncbi.nlm.nih.gov/pubmed/24162737
Web tool to search multiple public variant databases simultaneously and provide a unified interface to facilitate the search process. Used for integration of human and model organism genetic resources to facilitate functional annotation of the human genome. Used for analysis of human genes and variants by cross-disciplinary integration of records available in public databases to facilitate clinical diagnosis and basic research.
Neuroimaging facility that enables cutting-edge neuroscience research and training using non-invasive imaging methodologies, including both MRI and EEG.
An independent not-for-profit organization promoting in Europe the use of high quality Electronic Health Record systems (EHRs). One of its main missions is to support, as the European authorized certification body, EHRs certification development, testing and assessment by defining functional and other criteria. EuroRec is organized as a permanent network of National ProRec centers and provides services to industry (developers and vendors), healthcare providers (buyers), policy makers and patients.
Software application for matching a single candidate protein sequence and its modifications against a set of mass spectrometric observations. Used to analyze top-down mass spectrometry data.